Krebiozen

Krebiozen (also known as Carcalon) is a controversial substance that was promoted as a cancer treatment in the 1950s and 1960s. The substance was introduced by Dr. Andrew C. Ivy, a prominent physiologist and vice president of the University of Illinois. Despite initial claims of its effectiveness, subsequent scientific studies found no evidence that Krebiozen has any beneficial effect on cancer.

History

Krebiozen was first introduced in the United States in 1951 by Dr. Andrew C. Ivy. The substance was reportedly discovered by Dr. Stevan Durovic, a Yugoslavian doctor who claimed that it was an extract from horse blood that could cure cancer. Dr. Ivy, impressed by Durovic's claims, began promoting Krebiozen as a miracle cure for cancer.

Controversy

The promotion of Krebiozen as a cancer treatment led to one of the most controversial medical debates of the 20th century. The American Medical Association and the Food and Drug Administration (FDA) both challenged the claims made by Dr. Ivy and Dr. Durovic. In 1963, the FDA seized all supplies of Krebiozen and charged Dr. Ivy and Dr. Durovic with fraud. The case went to trial in 1966, and after a lengthy legal battle, the doctors were acquitted.

Scientific Evaluation

Numerous scientific studies have evaluated the effectiveness of Krebiozen as a cancer treatment. These studies have consistently found no evidence that Krebiozen has any beneficial effect on cancer. The American Cancer Society has stated that "Krebiozen is considered ineffective as a treatment for cancer by the medical community."

Legacy

Despite the lack of scientific evidence supporting its effectiveness, Krebiozen remains a topic of interest in the history of cancer treatment. The controversy surrounding Krebiozen highlights the importance of rigorous scientific evaluation and regulatory oversight in the development and promotion of new medical treatments.

See Also

• Alternative cancer treatments
• History of cancer chemotherapy